Hematologic Malignancy
Grade 3a Follicular Lymphoma
CI-CAN-00007774Explore in graph →
Hematologic20 active trials
- NCIt
- C7191
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00007774Explore in graph →
Clinical trials
38 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (4)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03015896 | Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 36 | David Bond, MDOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT02568553 | Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Nov 26, 2025 | clinicaltrials |
| NCT01995669 |
| Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma |
| completed |
| Phase 1 / Phase 2 |
| 66 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Jun 24, 2025 |
| clinicaltrials |
| NCT03410901 | TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas | completed | Phase 1 | 14 | Ronald LevyOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT02927964 | TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma | completed | Phase 1 / Phase 2 | 21 | Robert LowskyOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT03010358 | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 24 | Alexey Danilov, MDOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT02950220 | Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 | 2 | Kami MaddocksOTHER | 1 | Jul 30, 2019 | clinicaltrials |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials